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Physiological Differences and
Similarities in Asthma and COPD
―Based on Respiratory Function
Testing―
Michiaki Mishima1
ABSTRACT
Physiological differences and similarities in asthma and COPD are documented based on respiratory function
testing. (1) The airflow reversibility is usually important for the diagnosis of asthma. However, patients with long
disease histories may have poor reversibility. The reversibility test in COPD is useful for predicting the treat-
ment response. (2) In some of the stable asthmatic patients without attack, the concave downslope of flow-
volume curve is present. In severe COPD, the flow in the second half of the curve is smaller than that of rest-
breathing. (3) Inspiratory capacity (IC) is a good estimator of air trapping and of predicting the exercise capacity
in COPD or persistent asthma. (4) Peak expiratory flow (PEF) can be an important aid in both diagnosis and
monitoring of asthma. PEF is not used in COPD because the main disorder is in the peripheral airway. (5)
Measurements of airway responsiveness may help to a diagnosis of asthma. However, many COPD cases
also have it. (6) Impulse oscillation system (IOS) revealed that the predominant airway disorders in asthma and
COPD are central and peripheral respiratory resistance, respectively. However, some asthma patients have
larger values of peripheral component. (7) DLCO reflects the extent of pathological emphysema and it is useful
for the follow-up of COPD, whereas DLCO is not decreased in asthma. (8) The patient with widened A-aDO2 and
alveolar hypoventilation may lead to the life threatening hypoxia in severe asthma attack or severe COPD.
When PaCO2 overcomes PaO2, the patient should immediately be treated by mechanical ventilation.
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INTRODUCTION
The physiological measurements of asthma and
COPD are considered to be indispensable tools to dif-
ferentiate these diseases and maintain an up-to-date
knowledge of the disease condition. The present re-
view will clarify the physiological differences and
similarities between asthma and COPD based on res-
piratory function testing, mainly according to GINA-
2007 (Global Strategy for Asthma Management and
Prevention) and GOLD-2008 (Global Initiative for
Chronic Obstructive Lung Disease).1,2
SPIROMETRY
The most characteristic feature of the lung function
during an asthma attack and COPD is the airflow
limitation. During an asthma attack, the airway lumen
becomes narrow due to airway smooth muscle
(ASM) contraction, mucosal edema and accumulation
of sputum. The airflow limitation is usually reversible.
However, in many cases with long disease histories,
the airflow limitation is irreversible due to airway re-
modeling. In COPD, the airflow limitation is chronic
and irreversible. It is caused by airway inflammation
mainly in peripheral lesions (bronchitis) and by pa-
renchymal destruction (emphysema), although the
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Fig. 1 Normal spirogram and spirogram typical of patients 
with asthma during moderate atack or moderate COPD (ref-
2). Type A: Normal. Type B: Asthma during moderate atack 
or moderate COPD.
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relative contributions of these factors vary from per-
son to person. An indispensable measurement to de-
tect airflow limitation is spirometry. The subject is
usually asked to expire with maximum effort from the
maximum inspiratory level (TLC: total lung capacity)
to the maximum expiratory (RV: residual volume)
level. There are two ways of analyzing the data: (1)
volume (Y axis)-time (X axis) curve, (2) flow (Y axis)-
volume (X axis) curve. Both of these methods are in-
formative for estimating the condition of asthma and
COPD.
VOLUME-TIME CURVE (FIG. 1)
The expired volume measured from the beginning to
the end of the forced expiratory maneuver is defined
as FVC (forced expiratory volume). Asthma and
COPD patients usually have normal FVC values.
However, the airways collapse when an expiratory
volume has been reached close to the level of the re-
sidual volume, at which stage the airflow limitation
becomes severe, and therefore FVC is decreased.
This situation leads to the “restrictive ventilatory dis-
order coupled with severe obstructive disorder”. The
expired volume during the initial one second is de-
fined as FEV1, %FEV1 is defined as 100 × FEV1pFEV
1, where pFEV1 is the predicted normal value calcu-
lated based on gender, age and height. FEV1% is de-
fined as 100 × FEV1FVC, and obstructive ventilatory
disorder is defined as “FEV1% < 70%”. In asthmatic pa-
tients, obstructive ventilatory disorder during an
asthma attack is usually reversible, and is completely
rescued by bronchodilators. However, patients with a
long disease history have irreversible obstructive dis-
order due to airway remodeling. Furthermore, asth-
matic patients with a history of smoking may have ir-
reversible obstructive disorder due to the comorbid-
ity of COPD. “FEV1% < 70% after bronchodilators” is
necessary for defining COPD. Accordingly, the stage
of COPD is defined from %FEV1, where 30%, 50% and
80% are the boundary values for the staging; I (mild),
II (moderate), III (severe), IV (very severe). FEV1% is
not used in the staging of COPD. FEV1% (=FEV1
FVC) does not adequately reflect the airflow limita-
tion in severe COPD because FVC as well as FEV1
are decreased in severe COPD. The same limitation
is present for asthmatic patients. %FEV1 is a better es-
timator of airflow limitation than FEV1%.
The bronchodilator reversibility is defined as an in-
crease in FEV1 that is both greater than 200 ml and
12% above the pre-bronchodilator FEV1.3 This means
that the 200 ml criterion is adopted in cases of pre-
bronchodilator FEV1 less than 1,666 ml, and that the
12% criterion is adopted in cases with FEV1 greater
than 1,666 ml. In asthma, a β2-agonist is usually used
as a bronchodilator. The airflow reversibility is impor-
tant for the diagnosis of asthma. However, patients
with long disease histories may have poor reversibil-
ity. In COPD, a β2-agonist or an anticholinergic
agent, or a combination of the two, is used. Despite
earlier hopes, neither bronchodilator reversibility nor
corticosteroid reversibility testing predicts disease
progression, whether judged by a decline in FEV1,
deterioration of health status, or frequency of exacer-
bations.4 Minor variations in initial airway caliber can
lead to different classifications of reversibility status
depending on the day of testing, and the lower the
pre-bronchodilator FEV1, the greater the chance of a
patient being classified as reversible, even when the
200 ml criterion is included. However, the reversibil-
ity test is useful for predicting the treatment response
and is diagnostic for some cases, for example, in pa-
tients with atypical histories, such as asthma in child-
hood and regular night waking with cough or
wheeze.
FLOW-VOLUME CURVE (FIG. 2)
The characteristics of the flow-volume curve are as
follows; (1) The flow of the first half of the downslope
reflects the condition of central and peripheral air-
ways, and the flow of the second half reflects the con-
dition of peripheral airways. (2) The second half of
the downslope is effort independent. Figure 2 shows
representative curves of asthma without attack
(FEV1% = 72.0%, %FEV1 = 82.0%) (A) and severe
COPD (FEV1% = 42.0%, %FEV1 = 28.2%) (B). The dot-
ted linear downslopes represent normal curves. Even
in the attack-free condition in the asthmatic patients,
the flow is decreased at the beginning of the
downslope, and the second half of the curve shows a
straight line (Fig. 2A). These findings are derived
from central airway flow limitations during the forced
expiratory maneuver, and are useful for making a di-
agnosis in the attack-free asthma. In COPD, the peak
expiratory flow is very low, and the downslope of the
curve is concave because of the severe airflow limita-
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Fig. 2 Flow-volume curve typical of patients with asthma without atack (A) and  severe COPD (B). ① De-
creased flow at the beginning of downslope, ②Straight line, ③Decreased peak flow,④Concave line, ⑤Flow 
less than that of rest breathing.
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tion in the peripheral airway. The flow limitation in
the peripheral airway in COPD is due to the following
two factors; (1) increased peripheral airway resis-
tance due to remodeling, (2) airway collapse during
the expiratory effort due to the decreased parenchy-
mal tethering. Parenchymal tethering is the suppor-
tive force of the lung tissue that keeps the airway lu-
men open, and it is decreased by the destruction of
the lung tissue seen in, for example, emphysema. In
some of the stable asthmatic patients without asthma
attack the concave downslope is present. This may be
informative in clarifying the remodeling of the periph-
eral airways in asthma. In some of the patients with
severe COPD, the flow in the second half of the curve
is smaller than that of rest-breathing (Fig. 2B). This
finding shows that the expiratory effort makes the pe-
ripheral airway collapse, and this indicates that the
airways are extremely collapsible and that the condi-
tion is extremely severe.
For the quantification of the downslope of the flow-
volume curve, V’25 and V’50 have been adopted. V’25
and V’50 are flow rates at the lung volume of RV (re-
sidual volume) plus VC × 0.25 and VC × 0.5, respec-
tively. A V’25 value less than 0.8 × predicted V’25 and
(V’50V’25 > 3.0) has been used as the criteria indicat-
ing an airflow limitation in the peripheral airway.
However, the value of V’25 has been reported to be
too small to provide reliable data. Recently, FEF25-75%
(mean forced expiratory volume from 25% to 75% VC
from RV) has been used as an indicator of the periph-
eral airway condition. However, it should be re-
minded that FEF25-75% is also highly affected by the
large airway condition.
LUNG VOLUME
The lung volume is composed of four elements: IRV
(inspiratory reserve volume), TV (tidal volume), ERV
(expiratory volume) and RV (residual volume). Four
kinds of lung capacity are defined from the complex
of the elements: IC (inspiratory capacity: IRV + TV),
FRC (functional residual capacity: ERV + RV), VC (vi-
tal capacity: IRV + TV + ERV) and TLC (total lung ca-
pacity: IRV + TV + ERV + RV). FRC, VC and TLC can-
not be measured by spirometry because they include
RV. There are two ways of measuring RV: The gas di-
lution method and the body plethysmographic
method. The gas dilution method (He dilution or N2
wash-out method) does not estimate the poorly venti-
lated air space. In contrast, the body plethysmog-
raphic method estimates all of the airspace in the
lung because the lung volume is calculated from the
volume change induced by compression of the tho-
racic wall. Thus, the difference in volume measured
by the two methods equals the poorly ventilated air
space, which increases in COPD with emphysema.
In COPD, TLC is increased because of hyperinfla-
tion of the lung, and RV is also increased because of
collapse of the peripheral airway in the early expira-
tory phase. However, the increase of RV overcomes
the increase of TLV, and VC and IC are decreased.
Thus, the severe COPD patient has both obstructive
and restrictive ventilatory impairment. Recently, “air
trapping” has been a topic of discussion. TV must be
increased during exercise, but complete expiration is
difficult in advanced COPD because of the airflow
limitation, resulting in an increase of ERV and a de-
crease of IC. This situation makes it difficult to in-
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Fig. 3 Lung volume in COPD at rest or during [on] 
exercise. ①VC and IC are decreased due to the increase of 
RV. ② These phenomena are amplified by exercise. ③
These phenomena may also be noted in persistent asthma.
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crease ventilation and becomes the cause of dyspnea
during exercise. IC is reported to be a good estimator
of air trapping and of predicting the exercise capacity
in COPD5 (Fig. 3).
All of these findings in lung volume cannot usually
be applied to asthma in the stable condition. How-
ever, in patients with persistent asthma or asthma
with a long history, similar findings may be obtained,
such as an increase of RV and decreases of VC and IC
due to the peripheral airway flow limitation.
PEAK EXPIRATORY FLOW (PEF)
PEF measurements are made using a peak flow me-
ter, and it can be an important aid in both diagnosis
and monitoring of asthma, but PEF is not used in
COPD because the main airway disorder of COPD is
in the peripheral airway. Modern PEF meters are
relatively inexpensive, portable, and ideal for patients
to use in home settings for day-to-day objective meas-
urements of airflow limitation. The clinical use of PEF
in asthma is as follows: (1) To confirm the diagnosis
of asthma. Although spirometry is the preferred
method of documenting airflow limitation, a 60 Lmin
(or 20% or more of prebronchodilator PEF) improve-
ment after inhalation of a bronchodilator, or diurnal
variations in PEF of more than 20% (with twice daily
readings, more than 10%) suggests a diagnosis of
asthma. (2) To improve control of asthma, particu-
larly in patients with poor perception of symptoms.
Asthma management plans that include self-
monitoring of symptoms or PEF for treatment of ex-
acerbations have been shown to improve asthma out-
comes. It is easier to discern the response to therapy
from a PEF chart than from a PEF diary, provided the
same chart format is consistently used.6 (3) To iden-
tify environmental (including occupational) causes of
asthma symptoms. This involves the patient monitor-
ing PEF daily or several times each day over periods
of suspected exposure to risk factors in the home or
workplace, or during exercise or other activities that
may cause symptoms, and during periods of non-
exposure.
However, measurements of PEF are not inter-
changeable with other measurements of lung func-
tion such as FEV1 in either adults7 or children.8 PEF
can underestimate the degree of airflow limitation,
particularly as airflow limitation and gas trapping
worsen. Because values for PEF obtained with differ-
ent peak flow meters vary and the range of predicted
values is too wide, PEF measurements should prefer-
ably be compared to the patient’s own previous best
measurements using hisher own peak flow meter.9
One method of describing diurnal PEF variability is
as the amplitude (the difference between the maxi-
mum and minimum values for the day), expressed as
a percentage of the mean daily PEF value. Another
method of describing PEF variability is by recording
the minimum morning pre-bronchodilator PEF over 1
week, expressed as a percent of the recent best PEF
value (Min%Max) (Fig. 4). This latter method has
been suggested to be the best PEF index of airway
lability for clinical practice because it requires only a
once-daily reading, correlates better than any other
index with airway hyperresponsiveness, and involves
only a simple calculation.
MEASUREMENT OF AIRWAY RESPONSIVE-
NESS
For patients with symptoms consistent with asthma,
but with normal lung function, measurements of air-
way responsiveness to direct airway challenges such
as inhaled methacholine and histamine or indirect
airway challenges such as inhaled mannitol or exer-
cise challenge may help establish a diagnosis of
asthma.10 Two methods are used for the measure-
ment. One is a traditional method using FEV1. The
test results are usually expressed as the provocative
concentration (or dose) of the agonist causing a given
fall (often 20%) in FEV1. However, this measurement
is applied only to patients who can perform a forced
expiratory maneuver, and the repeated forced expira-
tion may change lung mechanics. Another procedure
is a forced oscillation method, which measures the
change in respiratory resistance (Rrs) to a 3 Hz sinu-
soidal pressure wave driven from the mouth during
rest-breathing. The provocative dose of the agonist
causing an initial increase in Rrs is defined as the
“sensitivity”, and the rate of increase of the Rrs is de-
fined as the “specificity”.11 The forced oscillation
method has the advantage that it can be applied to
children or elderly patients who find it difficult to per-
form forced expiration.
These tests are sensitive for making a diagnosis of
asthma, but have limited specificity.12 This means
that a negative test can be useful to exclude a diagno-
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Fig. 4  Measuring PEF variability in asthma (Ref-1). PEF chart of a 27-year-old man with long-standing, 
poorly controled asthma, before and after the start of inhaled glucocorticosteroid treatment. With treatment, 
PEF levels increased, and PEF variability decreased, as seen by the increase in Min% Max (lowest morning 
PEF/highest PEF%) over 1 week.
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Fig. 5 Relationship between central (R20) and peripheral 
component (R5-R20) of respiratory resistance in asthma 
and COPD (Ref-16).
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sis of persistent asthma in a patient who is not taking
inhaled glucocorticosteroid treatment, but a positive
test does not always mean that a patient has asthma.
This is because airway hyperresponsiveness has
been described in patients with allergic rhinitis13 and
in those with airflow limitations caused by conditions
other than asthma, such as COPD.14
IMPULSE OSCILLATION SYSTEM (IOS)
IOS is a type of oscillation mechanics. Impulse pres-
sure waves ranging from 0 to 100 Hz are loaded from
the mouth of subjects during rest-breathing, and fre-
quency characteristics of the respiratory impedance
are calculated from the pressure and flow.15 The real
part of the impedance at low frequency: 5 Hz (R5)
and high frequency: 20 Hz (R20) are approximated to
reflect the total and distal components of the respira-
tory resistance, and R5-R20 is approximated to be the
peripheral component. Figure 5 shows the relation-
ship between R5 (central component) and R5-R20
(peripheral component) in asthma―with the smaller
FEV1 predicted to be less than 80%―and COPD. The
results suggest that the predominant airway disor-
ders in asthma and COPD are central and peripheral,
respectively.16 However, some asthma patients have
larger values of R5-R20, which means that the periph-
eral airway disturbance is also important for the con-
trol of asthma. A comparison of the aerosol size of the
corticosteroid inhalation agent relative to its thera-
peutic effect on asthma is shown in Figure 6.17 The
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Table 1
PaO2 = 150-PaCO2/0.8-AaDO2
EDCBAType
80 ↑324080 ↑40PaCO2
40 ↑40 ↑40 ↑1010AaDO2
mmHg10 ↓ ↓70 ↓60 ↓40 ↓90PaO2
Fig. 6 Efect of treatment on peripheral component (R5-R20) of respira-
tory resistance (Ref-17). p = 0.044 between the treatments. Inhalation of 
the smaler size aerosol (HFA-BDP) has more efective than the larger size 
(CFC-BDP) to improve R5-R20 (peripheral component).
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12-week inhalation of the smaller-size aerosol (HFA-
BDP) was more effective than the inhalation of larger
sizes (CFC-BDP) in improving R5-R20 (peripheral
component). As to the treatment of COPD, R5 is use-
ful in estimating the effect of muscarinic M2 receptor
inhibitor on the airway obstruction of COPD due to
the inhalation of dry cold air.18
IOS is an examination that is not dependent on ef-
fort, and it can be applied to children or old persons
who find it difficult to perform a forced expiratory ma-
neuver.19 IOS has the additional advantage that it can
measure the central and peripheral components of
respiratory impedance separately. One must be care-
ful and realize that R5 and R5-R20 are not equal to
central and peripheral airway resistance, respectively.
Both parameters include the influence of the lung tis-
sue - chest wall impedance and the parallel inhomo-
geneity of ventilation.
DIFFUSION CAPACITY (DLCO)
DLCO is an estimator of the diffusion capacity of the
lung using carbon monoxide. DLCO is calculated from
the speed of reduction of alveolar CO density after a
deep inspiration of CO (1%) and breath-holding (10
sec). The DLCO value is about the same as DLO2, and
it is easier to calculate than DLO2 because the partial
pressure of CO at the pulmonary capillary is negligi-
ble. The determinants of DLCO are (1) diffusion capac-
ity between alveoli and alveolar capillary, (2)
ventilation-perfusion distribution, (3) amount of the
alveolar capillary bed, and (4) Hb (hemoglobin) den-
sity.
DLCO is reported to reflect the extent of pathologi-
cal emphysema and it is an important index for the
follow-up of COPD.20 The decrease of DLCO in emphy-
sema is explained as originating from the decrease of
the capillary bed and the unevenness of ventilation-
perfusion distribution. Hb density is an important fac-
tor to consider. Some COPD patients may have ane-
mia due to their poor condition. In contrast, other pa-
tients may have a high Hb density because of their
nocturnal hypoxia and resulting erythropoietin pro-
duction. These situations may result in the underesti-
mation or overestimation of the diffusion capacity.
Thus DLCO must be corrected according to the Hb
density using the following formula and assuming
that the normal Hb density is 14.6 gdl.;
Corrected DLCO = Measured DLCO × (10.22 + Hb)
1.7 Hb.
DLCO has been documented to be increased in
asthma because of the increase of blood volume of
the capillary bed due to the lung congestion. How-
ever, this may not always be the case because un-
evenness of the ventilation-perfusion distribution may
cancel the increase of DLCO caused by the lung con-
gestion in asthma.
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ARTERIAL BLOOD GAS ANALYSIS (ABGA)
ABGA is the final output of the lung function, and the
deterioration of ABG may be fatal. The A-aDO2
(alveolar-arterial difference of oxygen) is important
for assessing the current condition of the lungs, and
it is calculated under the room air condition as fol-
lows:
A -aDO2 = 150 − PaCO20.8 − PaO2 ---- (A)
where 150 is the O2 pressure of the room air and 0.8
is a respiratory quotient.
The normal value of A-aDO2 is less than 20 mmHg.
which corresponds to PaCO2 = 40 mmHg, PaO2 = 80
mmHg. A ventilation-perfusion mismatch andor a
decrease of the diffusion capacity will widen the A-
aDO2. In the case of asthma, A-aDO2 is easily wid-
ened by the ventilation-perfusion mismatch during an
asthma attack because of the uneven bronchocon-
striction. In the case of COPD, the decrease of the al-
veolar capillary bed due to emphysema may be addi-
tive to the airway narrowing; the ventilation-perfusion
mismatch is highly variable, and the degree of A-
aDO2 widening varies considerably among patients.
Equation (A) can be transformed into (B) as fol-
lows:
PaO2 = 150 − PaCO20.8 − A-aDO2 ---- (B)
Equation (B) is useful for understanding the mecha-
nism of hypoxia, and 5 patterns are listed in Table 1.
Pattern-A is that of normal subjects. PaCO2 is recipro-
cally proportional to the alveolar ventilation, and a
normal PaCO2 value shows that alveolar ventilation is
normal. A normal A-aDO2 shows that a ventilation-
perfusion mismatch or diffusion impediment does not
exist. Thus, it is natural that PaO2 calculated from
equation (B) is normal. Pattern-B is that of neuro-
muscular disease. A-aDO2 is normal (normal lung),
but PaCO2 is twice the normal value, which repre-
sents an alveolar ventilation that is half of the normal.
These situations resulted in severe hypoxia. This situ-
ation cannot occur in asthma or COPD because alveo-
lar hypoventilation is usually associated with
ventilation-perfusion mismatch in asthma or COPD.
Pattern-C, D, E are various patterns of asthma and
COPD with widened A-aDO2. Asthma during a mild-
moderate attack or mild-moderate COPD usually has
pattern C. However, patients who are sensitive to hy-
poxia and have a potential to increase alveolar ventila-
tion, can show pattern D in an effort to overcome hy-
poxia (compensatory hyperventilation). However, the
severe conditions of an asthma attack or severe
COPD give rise to pattern-E, severe alveolar hypoven-
tilation and severe hypoxia. The causes of hypercap-
nea (alveolar hypoventilation) in a severe asthma at-
tack or severe COPD are (1) increase of physiological
dead space, (2) increase of airway resistance and (3)
muscle atrophy caused by steroid therapy or muscle
fatigue. It must be realized that the stridor tends to
be decreased during a severe asthma attack due to
the hypoventilation. The patient with widened A-
aDO2 and alveolar hypoventilation may succumb to
the life threatening hypoxia. When PaCO2 overcomes
PaO2, the patient should immediately be treated by
mechanical ventilation.
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